AZD7687 Multiple Ascending Dose Study

A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Multiple Ascending Doses in Overweight to Obese But Otherwise Healthy Male Subjects

The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures
• suitable veins for cannulation or repeated venepuncture.
• Have a body mass index (BMI) between 27 and 35 kg/m2

Exclusion Criteria:

• Fasting serum (S)-glucose ≥7.0 mmol/L or non-fasting S-glucose ≥11.1 mmol/L at screening.
• Any eating disorder or actively attempting to loose weight within 3 months prior to enrolment.
• Smoking more than 7 cigarettes per week from time of consent